- Home
- LPTX vs VRCA Comparison
LPTX vs VRCA Comparison
Compare LPTX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- VRCA
- Stock Information
- Founded
- LPTX 2011
- VRCA 2013
- Country
- LPTX United States
- VRCA United States
- Employees
- LPTX N/A
- VRCA N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- VRCA Health Care
- Exchange
- LPTX Nasdaq
- VRCA Nasdaq
- Market Cap
- LPTX 35.4M
- VRCA 40.6M
- IPO Year
- LPTX N/A
- VRCA 2018
- Fundamental
- Price
- LPTX $0.42
- VRCA $3.58
- Analyst Decision
- LPTX Hold
- VRCA Hold
- Analyst Count
- LPTX 1
- VRCA 3
- Target Price
- LPTX N/A
- VRCA $20.00
- AVG Volume (30 Days)
- LPTX 7.1M
- VRCA 374.9K
- Earning Date
- LPTX 11-13-2025
- VRCA 11-06-2025
- Dividend Yield
- LPTX N/A
- VRCA N/A
- EPS Growth
- LPTX N/A
- VRCA N/A
- EPS
- LPTX N/A
- VRCA N/A
- Revenue
- LPTX N/A
- VRCA $14,704,000.00
- Revenue This Year
- LPTX N/A
- VRCA $332.45
- Revenue Next Year
- LPTX N/A
- VRCA $12.85
- P/E Ratio
- LPTX N/A
- VRCA N/A
- Revenue Growth
- LPTX N/A
- VRCA 5.72
- 52 Week Low
- LPTX $0.22
- VRCA $3.43
- 52 Week High
- LPTX $4.24
- VRCA $16.19
- Technical
- Relative Strength Index (RSI)
- LPTX 42.80
- VRCA 33.87
- Support Level
- LPTX $0.43
- VRCA $3.44
- Resistance Level
- LPTX $0.56
- VRCA $3.96
- Average True Range (ATR)
- LPTX 0.06
- VRCA 0.27
- MACD
- LPTX -0.02
- VRCA -0.03
- Stochastic Oscillator
- LPTX 0.04
- VRCA 10.91
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.